<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02168933</url>
  </required_header>
  <id_info>
    <org_study_id>FP00004323</org_study_id>
    <secondary_id>10032937</secondary_id>
    <nct_id>NCT02168933</nct_id>
  </id_info>
  <brief_title>308nm Excimer Laser for Treatment of Fingernail Psoriasis</brief_title>
  <acronym>NAPSI</acronym>
  <official_title>Randomized Controlled Trial of 308 nm Excimer Laser for Treatment of Nail Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Society for Dermatologic Surgery</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Psoriasis is a common skin disease, which affects 2-3% of the population. Up to two third of
      patients with psoriasis develop nail changes. These visible changes can be painful and
      disabling and are associated with social stigma. Most topical treatments are only partially
      effective. Systemic treatments can have serious side effects. Excimer laser is a form of
      targeted ultraviolet light therapy that has been successfully used to treat isolated
      psoriatic plaques on difficult to treat areas such as scalp or palms. The purpose of this
      study is to investigate efficacy of excimer laser for treatment of fingernail psoriasis.
      Sixteen patients with stable fairly symmetric fingernail psoriasis will be enrolled. After
      obtaining informed consent, an investigator will evaluate the severity of nail psoriasis in
      each hand using an objective score, called Modified Nail Psoriasis Severity Index (mNAPSI).
      In a random fashion, one hand will be treated with excimer laser and the other hand will
      receive sham treatment. During the treatments, patients will wear protective eyewear that
      does not permit them to see which hand receives active treatment and which hand receives sham
      treatment. Patients will be treated twice a week for 8 weeks. At weeks 8, 12, and16 the
      investigator who is blinded to the treatment assignments will re-evaluate the fingernails
      using mNAPSI score. Mean change from baseline mNAPSI score at weeks 8, 12, and 16 in hands
      treated with excimer compared to hands treated with sham will be measured. We will also
      measure patient's assessment of severity of nail disease and the pain or any adverse events
      associated with laser treatments. Given the slow growth rate of fingernails, the final
      evaluations will be performed at week 16. In summary, this is the first controlled study to
      evaluate efficacy of excimer laser in fingernail psoriasis. If found to be effective, excimer
      laser could be used as a safe, locally administered treatment for recalcitrant nail
      psoriasis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Modified NAPSI Score (Nail Psoriasis Severity Index)</measure>
    <time_frame>at 16 weeks</time_frame>
    <description>This is an instrument that scores nail psoriasis severity. Severity for each nail is measured on a scale of 0-13, where crumbling, pitting, onycholysis and oil spots together are each graded 0-3, and other features (leukonychia, splinter hemorrhages, hyperkeratosis, and red spots in lunula) are scored 0 (absent) or 1 (present). Higher score indicates more severe nail psoriasis with 13 being the most severe and 0 being no nail disease present.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Assessment of Nail Psoriasis Activity</measure>
    <time_frame>at 16 weeks</time_frame>
    <description>this is a subjective patient reported scale, 0-100, where 100 is the most severe global assessment of the patient's nail psoriasis, and 0 is clear (no nail disease present).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Nail Psoriasis</condition>
  <arm_group>
    <arm_group_label>active excimer laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>308 nm excimer laser treatment: treatment with the laser by a dose protocol with increasing output.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham excimer laser</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham 308 nm excimer laser treatment: laser dose was administered with a cap that blocks all active UV passing through the device, therefore is a placebo, but because the procedure is the same, maintains a blind.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>308 nm excimer laser</intervention_name>
    <description>Biweekly treatments with 308 nm excimer laser for a total of 8 weeks</description>
    <arm_group_label>active excimer laser</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham laser</intervention_name>
    <description>Sham laser treatment to the control side biweekly for a total of 8 weeks.</description>
    <arm_group_label>Sham excimer laser</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must give written informed consent.

          -  Must be at least 18 years old.

          -  Must have been diagnosed with stable fingernail psoriasis.

          -  Must have fairly symmetric fingernail psoriasis in right and left hand with similar
             modified NAPSI scores in right and left hand target nails. Target nail is defined as
             the fingernail with highest modified NAPSI score.

          -  Must have active fingernail psoriasis, defined as a target fingernail matrix NAPSI
             score of at least 2 and modified NAPSI score from a combination of crumbling,
             onycholysis and pitting at least 2. •

          -  No changes in the systemic therapy or nail directed topical therapy during the 16 week
             study period.

        Exclusion criteria:

          -  Subjects unable to tolerate frequency of visits.

          -  History of intolerance to or worsening of psoriasis with ultraviolet light.

          -  Current use of known photosensitizing medications.

          -  History of Fitzpatrick Type I skin, photosensitivity, or keloid formation.

          -  Any new systemic psoriasis therapy including biologics, conventional systemic
             immunomodulators, phototherapy, or nail directed topical therapy for the last 3 months
             prior to enrollment.

          -  Any other condition that in the eyes of the investigator will disqualify patient from
             the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Utah, Department of Dermatology</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Augustin M, Herberger K, Hintzen S, Heigel H, Franzke N, Schäfer I. Prevalence of skin lesions and need for treatment in a cohort of 90 880 workers. Br J Dermatol. 2011 Oct;165(4):865-73. doi: 10.1111/j.1365-2133.2011.10436.x.</citation>
    <PMID>21623753</PMID>
  </reference>
  <reference>
    <citation>Schäfer I, Rustenbach SJ, Radtke M, Augustin J, Glaeske G, Augustin M. [Epidemiology of psoriasis in Germany--analysis of secondary health insurance data]. Gesundheitswesen. 2011 May;73(5):308-13. doi: 10.1055/s-0030-1252022. Epub 2010 Jun 11. German.</citation>
    <PMID>20544588</PMID>
  </reference>
  <reference>
    <citation>de Jong EM, Seegers BA, Gulinck MK, Boezeman JB, van de Kerkhof PC. Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients. Dermatology. 1996;193(4):300-3.</citation>
    <PMID>8993953</PMID>
  </reference>
  <reference>
    <citation>Klaassen KM, van de Kerkhof PC, Pasch MC. Nail psoriasis: a questionnaire-based survey. Br J Dermatol. 2013 Aug;169(2):314-9. doi: 10.1111/bjd.12354.</citation>
    <PMID>23550612</PMID>
  </reference>
  <reference>
    <citation>van der Velden HM, Klaassen KM, van de Kerkhof PC, Pasch MC. Fingernail psoriasis reconsidered: a case-control study. J Am Acad Dermatol. 2013 Aug;69(2):245-52. doi: 10.1016/j.jaad.2013.02.009. Epub 2013 Mar 28.</citation>
    <PMID>23541759</PMID>
  </reference>
  <reference>
    <citation>de Vries AC, Bogaards NA, Hooft L, Velema M, Pasch M, Lebwohl M, Spuls PI. Interventions for nail psoriasis. Cochrane Database Syst Rev. 2013 Jan 31;(1):CD007633. doi: 10.1002/14651858.CD007633.pub2. Review.</citation>
    <PMID>23440816</PMID>
  </reference>
  <reference>
    <citation>Marx JL, Scher RK. Response of psoriatic nails to oral photochemotherapy. Arch Dermatol. 1980 Sep;116(9):1023-24.</citation>
    <PMID>7416754</PMID>
  </reference>
  <reference>
    <citation>[Narrow spectrum (311 nm) phototherapy in treatment of psoriatic nail]. Georgian Med News. 2009 Feb;(167):56-9. Russian.</citation>
    <PMID>19276472</PMID>
  </reference>
  <reference>
    <citation>Aubin F, Vigan M, Puzenat E, Blanc D, Drobacheff C, Deprez P, Humbert P, Laurent R. Evaluation of a novel 308-nm monochromatic excimer light delivery system in dermatology: a pilot study in different chronic localized dermatoses. Br J Dermatol. 2005 Jan;152(1):99-103.</citation>
    <PMID>15656808</PMID>
  </reference>
  <reference>
    <citation>Mudigonda T, Dabade TS, Feldman SR. A review of protocols for 308 nm excimer laser phototherapy in psoriasis. J Drugs Dermatol. 2012 Jan;11(1):92-7. Review.</citation>
    <PMID>22206083</PMID>
  </reference>
  <reference>
    <citation>Mudigonda T, Dabade TS, West CE, Feldman SR. Therapeutic modalities for localized psoriasis: 308-nm UVB excimer laser versus nontargeted phototherapy. Cutis. 2012 Sep;90(3):149-54. Review.</citation>
    <PMID>23094316</PMID>
  </reference>
  <reference>
    <citation>Al-Mutairi N, Al-Haddad A. Targeted phototherapy using 308 nm Xecl monochromatic excimer laser for psoriasis at difficult to treat sites. Lasers Med Sci. 2013 Jul;28(4):1119-24. doi: 10.1007/s10103-012-1210-4. Epub 2012 Sep 28.</citation>
    <PMID>23053247</PMID>
  </reference>
  <reference>
    <citation>Asawanonda P, Anderson RR, Chang Y, Taylor CR. 308-nm excimer laser for the treatment of psoriasis: a dose-response study. Arch Dermatol. 2000 May;136(5):619-24.</citation>
    <PMID>10815855</PMID>
  </reference>
  <reference>
    <citation>Rich P, Scher RK. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol. 2003 Aug;49(2):206-12.</citation>
    <PMID>12894066</PMID>
  </reference>
  <reference>
    <citation>Aktan S, Ilknur T, Akin C, Ozkan S. Interobserver reliability of the Nail Psoriasis Severity Index. Clin Exp Dermatol. 2007 Mar;32(2):141-4. Epub 2006 Nov 27.</citation>
    <PMID>17137477</PMID>
  </reference>
  <reference>
    <citation>Cassell SE, Bieber JD, Rich P, Tutuncu ZN, Lee SJ, Kalunian KC, Wu CW, Kavanaugh A. The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. J Rheumatol. 2007 Jan;34(1):123-9.</citation>
    <PMID>17216680</PMID>
  </reference>
  <reference>
    <citation>Yaemsiri S, Hou N, Slining MM, He K. Growth rate of human fingernails and toenails in healthy American young adults. J Eur Acad Dermatol Venereol. 2010 Apr;24(4):420-3. doi: 10.1111/j.1468-3083.2009.03426.x. Epub 2009 Sep 8.</citation>
    <PMID>19744178</PMID>
  </reference>
  <reference>
    <citation>Ortonne JP, Paul C, Berardesca E, Marino V, Gallo G, Brault Y, Germain JM. A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis. Br J Dermatol. 2013 May;168(5):1080-7. doi: 10.1111/bjd.12060.</citation>
    <PMID>23013207</PMID>
  </reference>
  <reference>
    <citation>de Jong EM, Menke HE, van Praag MC, van De Kerkhof PC. Dystrophic psoriatic fingernails treated with 1% 5-fluorouracil in a nail penetration-enhancing vehicle: a double-blind study. Dermatology. 1999;199(4):313-8.</citation>
    <PMID>10640840</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>June 18, 2014</study_first_submitted>
  <study_first_submitted_qc>June 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2014</study_first_posted>
  <results_first_submitted>October 3, 2016</results_first_submitted>
  <results_first_submitted_qc>July 31, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 20, 2019</results_first_posted>
  <last_update_submitted>September 9, 2019</last_update_submitted>
  <last_update_submitted_qc>September 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Kristina Callis</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>psoriasis</keyword>
  <keyword>nail</keyword>
  <keyword>laser</keyword>
  <keyword>excimer</keyword>
  <keyword>treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Study Participants</title>
          <description>all participants received 308 nm excimer laser treatment on one hand, and sham laser treatment on the other hand
308 nm excimer laser: Biweekly treatments with 308 nm excimer laser for a total of 8 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>all study participants received 308 nm excimer laser treatment to one hand and sham laser to the other hand.
308 nm excimer laser: Biweekly treatments with 308 nm excimer laser for a total of 8 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" lower_limit="19" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Modified NAPSI Score (Nail Psoriasis Severity Index)</title>
        <description>This is an instrument that scores nail psoriasis severity. Severity for each nail is measured on a scale of 0-13, where crumbling, pitting, onycholysis and oil spots together are each graded 0-3, and other features (leukonychia, splinter hemorrhages, hyperkeratosis, and red spots in lunula) are scored 0 (absent) or 1 (present). Higher score indicates more severe nail psoriasis with 13 being the most severe and 0 being no nail disease present.</description>
        <time_frame>at 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>308 nm excimer laser treatment
308 nm excimer laser: Biweekly treatments with 308 nm excimer laser for a total of 8 weeks
308 nm excimer laser: Laser to the non-control side</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>Sham laser treatment.
Sham laser: Biweekly treatments with Sham laser for a total of 8 weeks.
Sham laser: Sham laser treatment to the control side (308 nm excimer laser with cover in place preventing patient from exposure to laser energy).</description>
          </group>
        </group_list>
        <measure>
          <title>Modified NAPSI Score (Nail Psoriasis Severity Index)</title>
          <description>This is an instrument that scores nail psoriasis severity. Severity for each nail is measured on a scale of 0-13, where crumbling, pitting, onycholysis and oil spots together are each graded 0-3, and other features (leukonychia, splinter hemorrhages, hyperkeratosis, and red spots in lunula) are scored 0 (absent) or 1 (present). Higher score indicates more severe nail psoriasis with 13 being the most severe and 0 being no nail disease present.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="1.8"/>
                    <measurement group_id="O2" value="6.0" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Assessment of Nail Psoriasis Activity</title>
        <description>this is a subjective patient reported scale, 0-100, where 100 is the most severe global assessment of the patient's nail psoriasis, and 0 is clear (no nail disease present).</description>
        <time_frame>at 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>308 nm excimer laser treatment
308 nm excimer laser: Biweekly treatments with 308 nm excimer laser for a total of 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>Sham 308 nm excimer laser treatment
Sham laser: Sham laser treatment to the control side.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Assessment of Nail Psoriasis Activity</title>
          <description>this is a subjective patient reported scale, 0-100, where 100 is the most severe global assessment of the patient's nail psoriasis, and 0 is clear (no nail disease present).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.6" spread="33.0"/>
                    <measurement group_id="O2" value="55.4" spread="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected over 16 weeks (entire time of participation for each subject from screening to termination.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Active</title>
          <description>308 nm excimer laser treatment
308 nm excimer laser: Biweekly treatments with 308 nm excimer laser for a total of 8 weeks</description>
        </group>
        <group group_id="E2">
          <title>Sham</title>
          <description>Sham laser treatment (laser covered with cap so that the patient is not exposed to laser energy)
Sham laser: Biweekly treatments with Sham laser for a total of 8 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kristina Callis-Duffin</name_or_title>
      <organization>University of Utah, Derpartment of Dermatology</organization>
      <phone>8015816465</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

